01302nas a2200253   4500000000100000008004100001653001200042653001900054653001900073100001100092700001400103700001300117700001600130700001500146700001200161700001200173700001900185245007900204856006700283300001200350490000700362520066500369022001401034       2023                            d10aLeprosy10aanti-M. Leprae10aIgM antibodies1 aLema T1 aBobosha K1 aKasang C1 avan Hooij A1 aMengiste A1 aGeluk A1 aAseffa 1 aWoldeamanuel Y00aIncreased anti-M. Leprae PGL-I igm levels in a child who developed leprosy  uhttps://www.ajol.info/index.php/emj/article/view/252306/238370  a293-2950 v603 a<p>As part of a study that aimed at reaching those at risk of developing leprosy through screening of household contacts, a child aged 7 was included as contact of a multibacillary leprosy patient. This study was conducted in Kokosa, hot spot area in Oromia Region, Ethiopia. Compared to other contacts, this child showed increased levels of anti-M. leprae Phenolic glycolipid-I (PGL-I) IgM antibodies as assessed by up-converting lateral flow assay (UCP -LFA) at initial and second-time screening and developed leprosy three years later. Therefore, the anti-PGL-I IgM UCP-LFA can serve as an additional diagnostic field tool in leprosy control programs.</p>
  a2415-2420